AMGN vs CORT
AMGN: A global biotechnology innovator producing biologics, monoclonal antibodies, and small molecules across oncology, cardiovascular, inflammation, and bone health, navigating complex U.S. Medicare pricing pressures. CORT: Corcept Therapeutics is a commercial-stage biotechnology company pioneering cortisol modulation therapies to treat severe endocrine, oncologic, and metabolic conditions.
Side-by-side fundamentals
| Metric | AMGN | CORT | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $376.26 | $91.12 | |
| Market cap as of 2026-08-03 | $203.1B | $9.8B | |
| P/E as of 2026-08-03 | 26.65 | 261.41 | AMGN lower |
| PEG as of 2026-08-03 | 5.48 | n/a | |
| Net margin as of 2026-08-03 | +21.0% | +6.2% | AMGN higher |
| Gross margin as of 2026-08-03 | +74.0% | +98.3% | CORT higher |
| Operating margin as of 2026-08-03 | +28.8% | -1.1% | AMGN higher |
| ROE as of 2026-08-03 | +89.4% | +7.4% | AMGN higher |
| ROA as of 2026-08-03 | +8.6% | +5.8% | AMGN higher |
| Debt / equity as of 2026-08-03 | 6.24 | 0.00 | CORT lower |
| Revenue growth (YoY) as of 2026-08-03 | +9.1% | +12.2% | CORT higher |
| Revenue CAGR (3y) SEC XBRL | +11.8% | +23.7% | CORT higher |
| Dividend yield as of 2026-08-03 | +2.6% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | 0 | AMGN higher |
| Beta as of 2026-08-03 | 0.42 | 0.47 | |
| 1-year return as of 2026-07-27 close | +22.7% | +33.4% | CORT higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.